What is KeyCorp's Forecast for LFCR Q1 Earnings?

Key Points

• KeyCorp estimates Lifecore Biomedical will report a Q1 2026 earnings per share of ($0.31) and has a "Sector Weight" rating on the stock.
• Other analysts have mixed opinions, with William Blair rating it "outperform" and Wall Street Zen upgrading it to "hold"; currently, the consensus rating is a "Moderate Buy".
• Lifecore Biomedical reported a revenue of $36.44 million for the last quarter but missed the earnings estimate, reflecting challenges in its financial performance.

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) - Equities research analysts at KeyCorp issued their Q1 2026 earnings per share estimates for Lifecore Biomedical in a report released on Wednesday, September 3rd. KeyCorp analyst P. Knight anticipates that the company will earn ($0.31) per share for the quarter. KeyCorp has a "Sector Weight" rating on the stock. The consensus estimate for Lifecore Biomedical's current full-year earnings is ($0.91) per share. KeyCorp also issued estimates for Lifecore Biomedical's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.46) EPS.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%.The firm had revenue of $36.44 million during the quarter, compared to analyst estimates of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS.

A number of other research firms also recently commented on LFCR. Wall Street Zen upgraded Lifecore Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair assumed coverage on Lifecore Biomedical in a report on Wednesday, May 21st. They set an "outperform" rating on the stock. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Lifecore Biomedical presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Lifecore Biomedical Stock Down 5.2%

NASDAQ:LFCR traded down $0.41 during mid-day trading on Friday, reaching $7.53. The stock had a trading volume of 138,549 shares, compared to its average volume of 104,664. The business's 50 day moving average is $7.62 and its 200 day moving average is $6.93. Lifecore Biomedical has a fifty-two week low of $4.33 and a fifty-two week high of $8.85. The stock has a market cap of $281.70 million, a P/E ratio of -5.75 and a beta of 0.64. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. State of Wyoming acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $69,000. Tactive Advisors LLC acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $126,000. Grizzlyrock Capital LLC acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $5,964,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $88,000. Finally, Pale Fire Capital SE acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $249,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.